Velcera's business model includes effective and mutually beneficial partnering relationships with global animal health companies, contract research organizations, contract pharmaceutical manufacturers and others to develop, register and commercialize Promist™-based pet medicines.

As a patented technology, Promist attracts strategic partners by product differentiation through convienence, pharmacoknetic advantage of potential raised absorbsion and improved bioavailability and extension of the patent life of medication. Current collaborations include formulation and manufacturing relationships with The Chao Center at the University of Purdue, Coldstream Laboratories in Lexington, Kentucky and Argenta Manufacturing Ltd. of New Zealand.

Business development contact:

Dennis Steadman
President and CEO,
Phone: 267-757-3600
Fax: 267-757-3601
dsteadman@velcera.com